LAVA Therapeutics N.V. ( LVTX) Stock. Should you Buy or Sell? $ 2.50
-0.19 (-8.23 %)
LAVA Therapeutics N.V. Analysis
Updated on 10-09-2022| Symbol | LVTX |
| Price | $2.50 |
| Beta | 0.000 |
| Volume Avg. | $6.36 thousand |
| Market Cap | $64.44 M |
| 52 Week Range | $2.28 - $8.38 |
LAVA Therapeutics N.V. opened the day at $2.50 which is -8.23 % on yesterday's close. LAVA Therapeutics N.V. has a 52 week high of $8.38 and 52 week low of $2.28, which is a difference of $6.1. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $64.44 M and total net profit is $5000000 which means the company is trading at 12.89 times profit to market capitalization. Theoretically, if you were to buy LAVA Therapeutics N.V. for $64.44 M, it would take 15 years to get your money back. LAVA Therapeutics N.V. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
LAVA Therapeutics N.V. Stock Forecast - Is LAVA Therapeutics N.V. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | 0.263 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -7.743 |
Valuing LAVA Therapeutics N.V.
| Price Book Value Ratio | 0.594 | Price To Book Ratio | 0.594 |
| Price To Sales Ratio | 12.687 | Price Earnings Ratio | -1.639 |
How liquid is LAVA Therapeutics N.V.
| Current Ratio | 7.754 |
| Quick Ratio | 7.654 |
Debt
| Debt Ratio | 0.163 | Debt Equity Ratio | 0.195 |
| Long Term Debt To Capitalization | 0.042 | Total Debt To Capitalization | 0.045 |
Latest news about LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held virtually and in New York City.
LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST
LAVA Therapeutics (LVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.
UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.
About LAVA Therapeutics N.V.
Description :
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
